Solid Tumors

The majority of cancers arise in major organs and are collectively referred to as solid tumors. According to the American Cancer Society, approximately 1.5 million new cases are expected to be diagnosed in 2009. The specific solid tumor subtype and stage of disease determines initial treatment, which may include chemotherapy, radiation therapy, surgery or a combination of therapies. Although many patients respond to treatment, many eventually relapse and become resistant to treatment, underscoring the need for additional treatment options.

Onyx is currently testing carfilzomib in an ongoing Phase 1/2b trial evaluating its safety and efficacy as a single-agent in patients with recurrent or advanced solid tumors in non-small cell lung cancer, small cell lung cancer, ovarian cancer and kidney cancer.

For a more comprehensive list of carfilzomib clinical trials, please visit clinicaltrials.gov.

Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma - 007
Enrollment in Phase 1b complete – Phase 2 portion ongoing
Study Design: Non-randomized, open label, single group assignment
Patients: Phase 1 patients have either relapsed solid tumors or relapsed/refractory multiple myeloma; Phase 2 patients have either relapsed solid tumors or newly diagnosed multiple myeloma
Purpose: To evaluate safety and tolerability as well as overall response rate in the Phase 2 trial
Location: Multiple centers throughout the U.S.

Stock Quote (update every 15 minutes): As of 4:00pm - 5/20/2011

  • Symbol
    ONXX
  • Last
    43.71 +0.22
  • Open
    43.46
  • High
    43.81
  • Low
    42.49
  • Volume
    1139204